Limits...
Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Liu Y, Teng Z, Wang Y, Gao P, Chen J - Med. Sci. Monit. (2015)

Bottom Line: No significant heterogeneity was observed among included studies (P>0.01, I2<50%).Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02).I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).

ABSTRACT

Background: Osteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients.

Material and methods: Online electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.

Results: Overall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.

Conclusions: Our results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

No MeSH data available.


Related in: MedlinePlus

The search process.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4588668&req=5

f1-medscimonit-21-2877: The search process.

Mentions: A total of 20 studies were finally included after applying the inclusion criteria. Figure 1 presents the selection process. The 20 articles (2 in English [25,26] and 18 in Chinese [27–44]) included 1030 osteosarcoma patients. All of them were conducted in Chinese populations. The sample size ranged from 27 to 95 subjects. Survivin expression was measured by HIC method, and was detected in 68.6% of all cases (707/1030). The main characteristics of included studies are shown in Table 1.


Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Liu Y, Teng Z, Wang Y, Gao P, Chen J - Med. Sci. Monit. (2015)

The search process.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4588668&req=5

f1-medscimonit-21-2877: The search process.
Mentions: A total of 20 studies were finally included after applying the inclusion criteria. Figure 1 presents the selection process. The 20 articles (2 in English [25,26] and 18 in Chinese [27–44]) included 1030 osteosarcoma patients. All of them were conducted in Chinese populations. The sample size ranged from 27 to 95 subjects. Survivin expression was measured by HIC method, and was detected in 68.6% of all cases (707/1030). The main characteristics of included studies are shown in Table 1.

Bottom Line: No significant heterogeneity was observed among included studies (P>0.01, I2<50%).Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02).I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).

ABSTRACT

Background: Osteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients.

Material and methods: Online electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.

Results: Overall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.

Conclusions: Our results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

No MeSH data available.


Related in: MedlinePlus